8 research outputs found
Early and subtle abnormalities of left ventricular function in clinically stable coronary artery disease patients with normal ejection fraction
No full textComplicanze operatorie di terapia riparativa chirurgica di pazienti vasculopatici. Relazione con rilievi preoperatori.
No full textRegorafenib in metastatic colorectal cancer
No full textRegorafenib is an oral multikinase inhibitor that blocks the activity of protein kinases involved in the regulation of tumor angiogenesis (VEGFR1, 2, 3; angiopoietin-1 receptor), oncogenesis (stem cell growth factor receptor; RET; BRAF including BRAFV600E), and tumor microenvironment (PDGFR-\u3b2 and FGFR). Based on data from the Phase III CORRECT study, regorafenib stands as a further option for patient affected by metastatic colorectal cancer who have exhausted previous available therapies. Its multi-targeted effect might explain activity in advanced lines of treatment, when cancer cells have been heavily challenged with previous lines of therapy and potentially developed multiple mechanisms of resistance, but also makes difficult to identify predictive biomarkers. In this article we examine preclinical as well as clinical data of regorafenib in the therapy of metastatic colorectal cancer, challenges for potential markers of efficacy and its role in the treatment algorithm
Detection of early abnormalities of left ventricular function by haemodynamic, echo-tissue doppler imaging and mitral doppler flow techniques in patients with coronary artery disease and normal ejection fraction
No full textRelation between left atrial spontaneous echocontrast and pulmonary venous flow in nonvalvular atrial fibrillation: implications for stratification of thromboembolic risk
No full textEffect of dobutamine on left ventricular relaxation and filling phase in patients with ischemic heart disease and preserved systolic function
No full text
